CH Biotech R&D Co., Ltd.

CH Biotech R&D Co., Ltd.

TTWSE:6534
84.30
TWD
+0.30
(+0.36%)
6.43EPS
14.10P/E
9.16BMarket Cap
Mar 03Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
12.31
5.51
7.55
8.4
9.09
8.66
7.23
10.49
14.77
15.57
15.91
17.7
20.32
Basic EPS, GAAP
- -
6.68
2.21
2.8
3.12
2.95
1.96
1.03
3
4.79
4.76
4.63
4.51
6.45
Free Cash Flow per Basic Share
- -
1.7
2.18
-0.62
-6.11
-2.09
1.71
1.28
1.98
5.99
5.58
-0.5
4.49
10.88
Dividend per Share
- -
- -
1
1.99
0.25
1.49
0.62
0.91
0.43
1.3
4.87
3.59
4.1
- -
Book Value per Share
0.06
4.35
5.63
6.42
10.21
13.93
15.23
15.24
17.75
21.5
24.52
25.74
26.13
26.14
Tangible Book Value per Share
0.06
4.19
5.44
6.26
10.06
13.79
15.09
15.13
17.67
21.42
24.46
25.68
26.02
25.97
Basic Weighted Avg Shares
93
16
93
92
93
97
97
97
97
97
97
103
103
102
Sales/Revenue/Turnover
- -
192
511
698
781
880
841
702
1,019
1,434
1,515
1,636
1,819
2,078
Operating Margin (%)
- -
65.25
47.24
49.08
48.36
41.88
30.67
20.66
35.27
35.64
37.35
33.15
34.87
42.41
Depreciation Expense
- -
3
24
33
35
51
88
98
97
140
166
190
214
219
Net Income, GAAP
- -
104
205
258
290
285
190
100
291
465
463
476
464
659
Effective Tax Rate (%)
- -
17
20.28
20.55
18.37
21.44
21.38
21.38
18.95
17.74
19.98
19.78
18.47
16.6
Profit Margin (%)
- -
54.28
40.06
37.01
37.18
32.44
22.66
14.26
28.62
32.45
30.58
29.12
25.51
31.73
Working Capital
6
340
240
176
-603
213
34
-8
126
336
353
206
150
89
LT Debt
- -
- -
159
299
146
950
934
950
777
633
241
326
166
168
Total Equity
6
404
523
596
944
1,352
1,478
1,480
1,723
2,088
2,520
2,647
2,686
2,635
Return on Invested Capital (%)
- -
48.16
32.95
30.08
20.29
12.4
7.53
4.13
10.18
14.09
13.87
12.6
14.81
20.07
Return on Capital (%)
- -
50.77
37.87
30.63
20.12
13.62
7.96
4.31
10.76
16.45
15.02
14.47
14.18
19.36
Return on Common Equity (%)
- -
50.77
44.21
46.22
37.71
24.86
13.46
6.77
18.2
24.43
20.11
18.44
17.4
24.82

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
498
493
701
LT Borrowings
32
- -
38
LT Finance Leases
135
135
130
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
103
103
101
Market Capitalization
9,252
8,892
9,163

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
872
1,351
1,092
Cash, Cash Equivalents & STI
397
635
644
Accounts Receivable, Net
246
479
183
Inventories
143
140
170
Total Current Liabilities
722
1,256
1,003
Payables & Accruals
- -
- -
- -
ST Debt
498
493
701
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.99%
12.96%
1.48%
Free Cash Flow
-36.12%
-170.97%
-995.82%
Net Income, GAAP
20.66%
50.09%
-2.6%
Sales/Revenue/Turnover
15.08%
22.14%
11.21%
Total Cash Common Dividend
93.04%
82.79%
14.21%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
825
401
135
275
1,636
2025
854
420
- -
328
1,819
2026
870
459
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4.08
1.27
-0.89
0.19
4.63
2025
3.89
0.37
- -
0.43
4.51
2026
4.15
1.49
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.5
- -
3.59
2025
- -
- -
- -
- -
4.1
2026
- -
- -
- -
- -
- -

Company Description

CEO
Cho Chun Huang
Full Time Employees
209
Sector
Process industries
Industry
Chemicals: agricultural
Address
No. 89, Wenxian Road Nantou NTC Taiwan 54041
IPO Date
Dec 21, 2023
Website
chbio.com
Business
CH Biotech R&D Co., Ltd. (6534.TW) develops and manufactures active pharmaceutical ingredients (APIs), key starting materials (KSMs), and advanced intermediates primarily for the anti-diabetic and cardiovascular drug markets; its core offerings include generic APIs such as Sitagliptin, Vildagliptin, Linagliptin, Dapagliflozin, and Empagliflozin under strict cGMP compliance, alongside custom synthesis services and biocatalysis technologies leveraging enzymatic processes for chiral compounds. The company operates production facilities in Taiwan and serves global pharmaceutical clients in North America, Europe, and Asia, with headquarters in Taoyuan City, Taiwan, where it was founded in 2006. In recent developments, CH Biotech expanded its manufacturing capacity through a new biocatalysis plant commissioned in 2024 to meet rising demand for green chemistry solutions; it formed a strategic partnership with a major European pharma firm in mid-2025 for co-development of novel GLP-1 receptor agonist intermediates and secured a NT$500 million funding round in late 2024 to support R&D in oligonucleotide APIs. These initiatives mark a shift toward high-value biologics and sustainable production, complementing its established small-molecule portfolio.